EU regulators to probe Johnson & Johnson's Takeda deal

This post was originally published on this site

The European Commission set an Aug. 10 deadline for its decision on the deal.

Japan’s biggest drugmaker announced the disposal of $10 billion worth of assets to cut debt in May last year, and also said it was selling TachoSil, a surgical patch for bleeding control, to Johnson & Johnson’s Ethicon for $400 million.

Add Comment